» Articles » PMID: 31151271

An Algal Metabolite-Based PPAR-γ Agonist Displayed Anti-Inflammatory Effect Via Inhibition of the NF-κB Pathway

Overview
Journal Mar Drugs
Publisher MDPI
Specialties Biology
Pharmacology
Date 2019 Jun 2
PMID 31151271
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

In our previous study, a synthetic compound, (+)-(,)-, that incorporated the key structures of anti-inflammatory algal metabolites and the endogenous peroxisome proliferator-activated receptor γ (PPAR-γ) ligand 15-deoxy-∆-prostaglandin J (15d-PGJ), exerted significant PPAR-γ transcriptional activity. Because PPAR-γ expressed in macrophages has been postulated as a negative regulator of inflammation, this study was designed to investigate the anti-inflammatory effect of the PPAR-γ agonist, (+)-(,)-. Compound (+)-(,)- displayed in vitro anti-inflammatory activity in lipopolysaccharides (LPS)-stimulated murine RAW264.7 macrophages. Compound (+)-(,)- suppressed the expression of proinflammatory factors, such as nitric oxide (NO), inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), possibly by the inhibition of the nuclear factor-κB (NF-κB) pathway. In macrophages, (+)-(,)- suppressed LPS-induced phosphorylation of NF-κB, inhibitor of NF-κB α (IκBα), and IκB kinase (IKK). These results indicated that PPAR-γ agonist, (+)-(,)- exerts anti-inflammatory activity via inhibition of the NF-κB pathway.

Citing Articles

The Associations between Asprosine, Clusterin, Zinc Alpha-2-Glycoprotein, Nuclear Factor Kappa B, and Peroxisome Proliferator-Activated Receptor Gamma in the Development of Complications in Type 2 Diabetes Mellitus.

Senyigit A, Durmus S, Tabak O, Oruc A, Uzun H, Ekinci I J Clin Med. 2024; 13(20).

PMID: 39458076 PMC: 11508428. DOI: 10.3390/jcm13206126.


Metabolic fate of the natural anticancer agent cucurbitacin B: an LC-MS/MS-enabled profiling of its major phase I and II conjugates in vivo.

Liu W, Xu D, Meng H, Wang C, Feng X, Wang J Anal Bioanal Chem. 2024; 416(29):7043-7062.

PMID: 39441433 DOI: 10.1007/s00216-024-05608-y.


Chronic exposure to low-level lipopolysaccharide dampens influenza-mediated inflammatory response A20 and PPAR network.

Gu Y, Chen-Yu Hsu A, Zuo X, Guo X, Zhou Z, Jiang S Front Immunol. 2023; 14:1119473.

PMID: 36726689 PMC: 9886269. DOI: 10.3389/fimmu.2023.1119473.


The Nutritional Properties, Chemical Compositions, and Functional Characteristics of the Aerial Parts of .

Dai L, Li B, Yang X, Wang Y, Pan H, Zhang J Front Nutr. 2022; 9:850714.

PMID: 35495930 PMC: 9053748. DOI: 10.3389/fnut.2022.850714.


The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.

Escandon P, Vasini B, Whelchel A, Nicholas S, Matlock H, Ma J Exp Eye Res. 2021; 208:108617.

PMID: 34010603 PMC: 8594540. DOI: 10.1016/j.exer.2021.108617.


References
1.
Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M . Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 2000; 403(6765):103-8. DOI: 10.1038/47520. View

2.
Straus D, Pascual G, Li M, Welch J, Ricote M, Hsiang C . 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A. 2000; 97(9):4844-9. PMC: 18320. DOI: 10.1073/pnas.97.9.4844. View

3.
Karin M, Ben-Neriah Y . Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000; 18:621-63. DOI: 10.1146/annurev.immunol.18.1.621. View

4.
Murphy G, Holder J . PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci. 2000; 21(12):469-74. DOI: 10.1016/s0165-6147(00)01559-5. View

5.
Tak P, Firestein G . NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001; 107(1):7-11. PMC: 198552. DOI: 10.1172/JCI11830. View